Hepatoblastoma is the most common malignant tumor of the liver during childhood and develops due to precursor cells of the liver cells. If treated early, a child’s survival can be prolonged by more than 5 years; if untreated, he or she can only survive for 1-2 years. Hepatoblastoma accounts for 90% of primary malignant tumors of the liver in children, and 80-90% of them occur in children aged 5 years old. If detected and treated at an early stage, it can effectively improve the survival rate of children. With the continuous development of current science, the survival period of hepatoblastoma has been prolonged, and comprehensive treatment is needed. According to the development of the child’s condition, surgery, chemotherapy, medication, transplantation and intervention can be appropriately selected to match the treatment. If treatment is given early, the survival of a child with hepatoblastoma can be extended by more than 5 years. If the treatment is late and detected late, the survival period of the child is shorter, and if the treatment is not timely, the child may only survive for 1-2 years. Parents are advised to avoid exposing their children to harmful substances and improve their own immunity. Within 2 weeks after hepatoblastoma surgery, the child must be supplied with adequate nutrition, including protein, vitamins and energy. Post-surgical chemotherapy in conjunction with combination therapy is especially important for pediatric liver malignancies.